The Allstate Corporation (ALL) is the largest publicly held personal-lines insurer in the United States, offering auto, home, and other property and casualty coverage. It is a stock, not an ETF, so this analysis is built around sell-side analyst price targets.
Because the overall mean of roughly 16 attributed targets sits only about 8% above the current price — too close to make a meaningful "can it reach" test — the central target used here is the average of the targets that are above the current price. That calculation lands at roughly $285, with an upside of about 14% from the recent close.
For context, the overall mean across the full target set is about $269, and the range is unusually wide at roughly $215 to $340. Bullish views cluster at the top: Bank of America carries a Buy with a $340 target, Raymond James a Strong Buy at $315, Piper Sandler and Roth each around $300, and JPMorgan, Mizuho, and UBS between roughly $275 and $295. In contrast, Citi (Sell, $215) and Barclays (Sell, $221) argue the stock is overvalued, while Morgan Stanley, Wells Fargo, and Goldman Sachs hold at $240, $236, and $250 respectively. HSBC upgraded the shares to Buy with a $266 target in October 2026, underscoring how split the Street remains.
Shares closed near $249.85 on October 20, 2026, leaving a required move of about 14% to reach $285 — a substantial but not extreme gain for a large-cap insurer. The stock has been volatile, trading in a 52-week range of $188.08 to $277.22 and pulling back from its July 2026 high before recovering.
The fundamental case rests on a sharp turnaround in profitability. In the third quarter of 2025, adjusted EPS (earnings per share) surged to $11.17 from $3.91 a year earlier as catastrophe losses fell to about $558 million from $1.7 billion. Results have remained strong into 2026, with quarterly revenue around $18.6 billion and earnings continuing to beat expectations. Allstate's trailing P/E (price-to-earnings) ratio of roughly 5 and return on equity near 40–50% reflect this earnings recovery, though they also help explain why some analysts argue the easy gains are already priced in.
The $277.22 July 2026 high is the most important resistance zone, sitting just below the $285 target. A durable breakout would require clearing that prior peak. On the downside, the $223–$226 area marked the early-October pullback low and offers near-term support, with the 200-day moving average near $226–$235 reinforcing that zone. The 50-day average near $246–$254 places the stock right at a key short-term pivot, making the current level a meaningful inflection point rather than a clean trend signal.
Analyst price targets generally reflect a research horizon of about 12 months, though individual firms differ. The most important near-term catalysts include Allstate's next earnings report (scheduled for early November 2026), guidance on premium growth and loss trends, and any updates on catastrophe exposure. Investors should also watch analyst revisions, competitive pricing signals from major auto insurers, and broader interest-rate and economic conditions that affect the insurer's investment income and the valuation of financial stocks.
For investors tracking names like Allstate alongside thousands of other opportunities, Tickeron's AI Daily Buy/Sell Signals provide a data-driven complement to traditional research. The system uses artificial intelligence to continuously monitor stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use the tool to discover new opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening allows. Explore the signals to see how an automated, AI-powered lens might sharpen your own market outlook.
Can Allstate reach $285? The question is a realistic one: the target, derived as the average of analyst price targets above the current price, requires a substantial but achievable 14% advance. Support comes from a genuine earnings and underwriting recovery, strong capital returns, and bullish targets as high as $340. The obstacles are equally real — competitive pricing, loss-cost inflation, catastrophe risk, and a notable group of Hold and Sell ratings that see the turnaround as largely complete. With the overall analyst mean near $269 and the full range stretching from roughly $215 to $340, the dispersion is wide, reflecting genuine disagreement about whether margins have further to run. The path to $285 depends most on sustained underwriting discipline and whether the stock can clear its $277 prior high. No outcome is guaranteed, and the target is a calculated reference point rather than a prediction.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ALL has been closely correlated with HIG. These tickers have moved in lockstep 81% of the time. This A.I.-generated data suggests there is a high statistical probability that if ALL jumps, then HIG could also see price increases.